Welch & Forbes LLC boosted its position in shares of Medtronic PLC (NYSE:MDT) by 9.7% in the second quarter, Holdings Channel.com reports. The firm owned 145,657 shares of the medical technology company’s stock after purchasing an additional 12,880 shares during the period. Welch & Forbes LLC’s holdings in Medtronic were worth $14,185,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MDT. Cordasco Financial Network acquired a new stake in shares of Medtronic in the first quarter worth about $27,000. Pin Oak Investment Advisors Inc. lifted its position in shares of Medtronic by 158.0% in the fourth quarter. Pin Oak Investment Advisors Inc. now owns 369 shares of the medical technology company’s stock worth $34,000 after buying an additional 226 shares during the last quarter. Spectrum Management Group Inc. lifted its position in shares of Medtronic by 353.8% in the first quarter. Spectrum Management Group Inc. now owns 413 shares of the medical technology company’s stock worth $38,000 after buying an additional 322 shares during the last quarter. Mackey Komara & Dankovich LLC acquired a new stake in shares of Medtronic in the first quarter worth about $38,000. Finally, Motco lifted its position in shares of Medtronic by 159.3% in the first quarter. Motco now owns 516 shares of the medical technology company’s stock worth $47,000 after buying an additional 317 shares during the last quarter. 80.00% of the stock is owned by hedge funds and other institutional investors.
In related news, SVP Richard Kuntz sold 3,438 shares of the business’s stock in a transaction dated Monday, July 22nd. The stock was sold at an average price of $101.12, for a total transaction of $347,650.56. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Carol A. Surface sold 9,000 shares of the business’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $97.66, for a total value of $878,940.00. The disclosure for this sale can be found here. Insiders sold 85,102 shares of company stock worth $8,244,274 over the last quarter. 0.28% of the stock is currently owned by corporate insiders.
Medtronic (NYSE:MDT) last posted its quarterly earnings data on Thursday, May 23rd. The medical technology company reported $1.54 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.07. The business had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.12 billion. Medtronic had a return on equity of 14.16% and a net margin of 15.15%. The firm’s revenue for the quarter was up .0% on a year-over-year basis. During the same period in the previous year, the company posted $1.42 earnings per share. On average, equities research analysts anticipate that Medtronic PLC will post 5.47 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, July 25th. Stockholders of record on Monday, July 8th were paid a $0.54 dividend. The ex-dividend date of this dividend was Friday, July 5th. This is a positive change from Medtronic’s previous quarterly dividend of $0.50. This represents a $2.16 dividend on an annualized basis and a dividend yield of 2.09%. Medtronic’s payout ratio is presently 41.38%.
MDT has been the subject of a number of analyst reports. Wells Fargo & Co raised Medtronic from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $100.00 to $110.00 in a research report on Tuesday, June 4th. ValuEngine cut Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. Royal Bank of Canada reduced their price target on Medtronic to $100.00 and set an “outperform” rating for the company in a research report on Tuesday, May 28th. Barclays set a $5.00 price target on Amneal Pharmaceuticals and gave the stock a “hold” rating in a research report on Thursday, July 11th. Finally, Northland Securities initiated coverage on THUNDER BRDG AC/SH SH in a research report on Thursday, June 20th. They issued an “outperform” rating for the company. Six investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Medtronic presently has a consensus rating of “Buy” and an average target price of $106.05.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.
Read More: Short Selling Stocks, A Beginner’s Guide
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.